- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Fuji and Olicon strike PACS alliance
Fuji Medical Systems USA and Olicon Imaging Systems this month signed a nonexclusive licensing and product distribution agreement. The deal enables Fuji, which has specialized in the development of computed radiography systems, to sell turnkey PACS
Fuji Medical Systems USA and Olicon Imaging Systems this month signed a nonexclusive licensing and product distribution agreement. The deal enables Fuji, which has specialized in the development of computed radiography systems, to sell turnkey PACS solutions to hospitals.
Under the terms of the agreement, Fuji will distribute Olicon's PACS products when customers desire a single-vendor solution for PACS and CR, according to Clay Larsen, managing director of marketing for Stamford, CT-based Fuji. Fuji can now directly offer its CR customers PACS products, whereas in the past, it had to refer them to another vendor, Larsen said.
San Clemente, CA-based Olicon, on the other hand, will license Fuji's CR image processing algorithms for use on Olicon's workstations, making them more suited for primary CR reading by radiologists, according to Dick Paulsen, Olicon's CEO. Olicon also believes the agreement will give the company an advantage in marketing its products to Fuji CR customers who are interested in upgrading to PACS.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
